HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation.

Yang H., Sun H., Brackenridge S., Zhuang X., Wing PAC., Quastel M., Walters L., Garner L., Wang B., Yao X., Felce SL., Peng Y., Moore S., Peeters BWA., Rei M., Canto Gomes J., Tomas A., Davidson A., Semple MG., Turtle LCW., Openshaw PJM., Baillie JK., Mentzer AJ., Klenerman P., ISARIC4C Investigators None., Borrow P., Dong T., McKeating JA., Gillespie GM., McMichael AJ.

Pathogen-specific CD8+ T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E-restricted CD8+ T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia-restricted anti-SARS-CoV-2 CD8+ T cells. HLA-E peptide-specific CD8+ T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E-restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.

DOI

10.1126/sciimmunol.abl8881

Type

Journal article

Journal

Science immunology

Publication Date

06/2023

Volume

8

Addresses

Centre for Immuno-Oncology, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Oxford, UK.

Keywords

ISARIC4C Investigators, CD8-Positive T-Lymphocytes, Humans, Antibodies, Histocompatibility Antigens Class II, Virus Replication, Down-Regulation, COVID-19, SARS-CoV-2

Permalink Original publication